Volume 16, Issue 2 (Mar-Apr 2022)                   mljgoums 2022, 16(2): 7-12 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Koohestani Y, Abdi A, Salehiyeh S, Pourmirzaei F, Çiftci M, Çoban O E. Protective Effect of Apigenin on Ovarian Follicles in Polycystic Ovary Syndrome-Induced Rats. mljgoums. 2022; 16 (2) :7-12
URL: http://mlj.goums.ac.ir/article-1-1316-en.html
1- Research & Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Koohestaniyy@gmail.com
2- Department of Physiology, Faculty of Medicine, Tehran University of medical Sciences, Tehran, Iran
3- Department of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4- Department of Animal Nutrition and Nutritional Diseases,Faculty of Veterinary Medicine, Firat University,Elazığ,Turkey
5- Department of Fish Processing Technology, Faculty of Fisheries, Firat University, Elazığ, Turkey
Abstract:   (267 Views)
Background and objectives: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders that affect fertility. In this syndrome, the rate of fibrotic tissue formation and structures such as collagen increases. This study intended to evaluate protective effect of apigenin on ovarian follicles in PCOS-induced female Wistar rats.
Methods: In this experimental study, 60 adult Wistar rats (weight: 200-250 g) were used. A vaginal test was performed to confirm induction of PCOS. Then, the rats were randomly divided into four groups: 1) control, 2) PCOS, 3) PCOS+apigenin (10 mg/kg), and 4) PCOS+apigenin (20 mg/kg). The rats in the experimental groups received apigenin solution via intrapertoneal injection for 14 days. Next, the ovarian tissue of animals was removed and subjected to histological studies. Data were analyzed using one-way ANOVA and Tukey's post hoc test. Statistical analysis of data was carried out in SPSS (version 20), and significance level was set to 0.05.
Results: The number of secondary cystic follicles in groups treated with apigenin (10 and 20 mg/kg) decreased significantly compared to the PCOS group (group2) (P≤0.05). Despite the reduction in the number of follicles, this reduction for the primary follicles was not statistically significant. Moreover, treatment with apigenin had no significant effect on the number of graph follicles (p≥0.05).
Conclusion: Our findings indicate that apigenin might be useful in controlling PCOS. Therefore, it may be suggested as a supplement to improve fertility of patients with PCOS.
Full-Text [PDF 982 kb]   (124 Downloads) |   |   Full-Text (HTML)  (69 Views)  
Research Article: Original Paper | Subject: Biochemistry
Received: 2020/08/30 | Accepted: 2020/09/9 | Published: 2022/03/7 | ePublished: 2022/03/7

1. Zangeneh FZ, Minaee B, Amirzargar A, Ahangarpour A, Mousavizadeh K. Effects of chamomile extract on biochemical and clinical parameters in a rat model of polycystic ovary syndrome. Journal of reproduction & infertility. 2010;11(3):169. [View at Publisher] [PubMed] [Google Scholar]
2. Goswami PK, Khale A, Ogale S. Natural remedies for polycystic ovarian syndrome (PCOS): a review. International journal of pharmaceutical and phytopharmacological research. 2012;1(6):396-402. [View at Publisher] [Google Scholar]
3. Ebejer K, Calleja-Agius J. The role of cytokines in polycystic ovarian syndrome. Gynecological Endocrinology. 2013;29(6):536-40. [View at Publisher] [DOI:10.3109/09513590.2012.760195] [PubMed] [Google Scholar]
4. Harira M. Use of Letrozole versus clomiphene-estradiol for treating infertile women with unexplained infertility not responding well to clomiphene alone, comparative study. Middle East Fertility Society Journal. 2018;23(4):384-7. [View at Publisher] [DOI:10.1016/j.mefs.2018.05.008] [Google Scholar]
5. Chiang L-C, Ng LT, Lin I-C, Kuo P-L, Lin C-C. Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer letters. 2006;237(2):207-14. [View at Publisher] [DOI:10.1016/j.canlet.2005.06.002] [PubMed] [Google Scholar]
6. Zheng P-W, Chiang L-C, Lin C-C. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life sciences. 2005;76(12):1367-79. [DOI:10.1016/j.lfs.2004.08.023] [PubMed] [Google Scholar]
7. Abazari O, Divsalar A, Ghobadi R. Inhibitory effects of oxali-Platin as a chemotherapeutic drug on the function and structure of bovine liver catalase. Journal of Biomolecular Structure and Dynamics. 2020;38(2):609-15. [View at Publisher] [DOI:10.1080/07391102.2019.1581088] [PubMed] [Google Scholar]
8. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang B-H. Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. The FASEB Journal. 2005;19(3):342-53. [View at Publisher] [DOI:10.1096/fj.04-2175com] [PubMed] [Google Scholar]
9. Liang Y-C, Huang Y-T, Tsai S-H, Lin-Shiau S-Y, Chen C-F, Lin J-K. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis. 1999;20(10):1945-52. [View at Publisher] [DOI:10.1093/carcin/20.10.1945] [PubMed] [Google Scholar]
10. Fang J, Zhou Q, Liu L-Z, Xia C, Hu X, Shi X, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1α and VEGF expression. Carcinogenesis. 2007;28(4):858-64. [DOI:10.1093/carcin/bgl205] [Google Scholar]
11. Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam M, Ghalandari B, Saboury AA. Probing the biological evaluations of a new designed Pt (II) complex using spectroscopic and theoretical approaches: Human hemoglobin as a target. Journal of Biomolecular Structure and Dynamics. 2016;34(5):1123-31. [View at Publisher] [DOI:10.1080/07391102.2015.1071280] [Google Scholar]
12. Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, et al. The therapeutic potential of apigenin. International journal of molecular sciences. 2019;20(6):1305. [View at Publisher] [DOI:10.3390/ijms20061305] [Google Scholar]
13. Abramovich D, Irusta G, Bas D, Cataldi NI, Parborell F, Tesone M. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology. 2012;153(7):3446-56. [View at Publisher] [DOI:10.1210/en.2012-1105] [PubMed] [Google Scholar]
14. Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin on Transforming Growth Factor-β-mediated Non-Smad Signaling Pathway, Oxidative Stress, and Pro‐inflammatory Cytokines Production with Human Vascular Smooth Muscle Cells. Iranian Journal of Allergy, Asthma and Immunology. 2019:1-10. [View at Publisher] [DOI:10.18502/ijaai.v19i1.2421] [PubMed] [Google Scholar]
15. Demirel MA, Ilhan M, Suntar I, Keles H, Akkol EK. Activity of Corylus avellana seed oil in letrozole-induced polycystic ovary syndrome model in rats. Revista Brasileira de Farmacognosia. 2016; 26(1): 83-8. [View at Publisher] [DOI:10.1016/j.bjp.2015.09.009] [Google Scholar]
16. Ghițu A, Schwiebs A, Radeke HH, Avram S, Zupko I, Bor A, et al. A comprehensive assessment of apigenin as an antiproliferative, proapoptotic, antiangiogenic and immunomodulatory phytocompound. Nutrients. 2019;11(4):858. [View at Publisher] [DOI:10.3390/nu11040858] [PubMed] [Google Scholar]
17. Bulut G, Kurdoglu Z, Dönmez YB, Kurdoglu M, Erten R. Effects of jnk inhibitor on inflammation and fibrosis in the ovary tissue of a rat model of polycystic ovary syndrome. International journal of clinical and experimental pathology. 2015;8(8):8774. [View at Publisher] [PubMed] [Google Scholar]
18. Hu S, Yu Q, Wang Y, Wang M, Xia W, Zhu C. Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Archives of gynecology and obstetrics. 2018; 297(5): 1081-8. [View at Publisher] [DOI:10.1007/s00404-018-4688-6] [PubMed] [Google Scholar]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.